Comparison
Why is bluebird bio, Inc. ?
- Poor long term growth as Net Sales has grown by an annual rate of 13.97% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -384.48
- RAW MATERIAL COST(Y) Fallen by -217.51% (YoY)
- NET SALES(Q) Highest at USD 38.71
- OPERATING PROFIT(Q) Highest at USD -5.96
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 0%, its profits have risen by 34.2%
- Promoters have decreased their stake in the company by -1.47% over the previous quarter and currently hold 1.09% of the company
- Promoters decreasing their stake may signify reduced confidence in the future of the business
How much should you hold?
- Overall Portfolio exposure to bluebird bio, Inc. should be less than 10%
- Overall Portfolio exposure to Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is bluebird bio, Inc. for you?
High Risk, Low Return
Quality key factors
Valuation Key Factors 
Technical key factors
Technical Movement
Fallen by -217.51% (YoY
Highest at USD 38.71 MM
Highest at USD -5.96 MM
Highest at -15.41 %
Highest at USD -25.87 MM
Highest at USD -25.97 MM
At USD 11.45 MM has Grown at 28.94%
Lowest at -546.55%
Lowest at USD 141.12 MM
Lowest at 1.61%
Here's what is working for bluebird bio, Inc.
Net Sales (USD MM)
Net Sales (USD MM)
Operating Profit (USD MM)
Operating Profit to Sales
Pre-Tax Profit (USD MM)
Pre-Tax Profit (USD MM)
Net Profit (USD MM)
Net Profit (USD MM)
Raw Material Cost as a percentage of Sales
Here's what is not working for bluebird bio, Inc.
Interest Paid (USD MM)
Cash and Cash Equivalents
Inventory Turnover Ratio






